⚡ Quick Answer
What is the Tylenol autism lawsuit? Families allege that Tylenol (acetaminophen) use during pregnancy increased the risk of autism spectrum disorder and ADHD in their children, and that Kenvue, Johnson & Johnson, and retailers who sold generic acetaminophen failed to warn of this risk despite scientific evidence. Federal cases were consolidated into MDL No. 3043 before Judge Denise Cote in the Southern District of New York. In 2024, Judge Cote excluded plaintiffs' expert testimony on causation and dismissed roughly 500 cases. On July 13, 2026, the 2nd U.S. Circuit Court of Appeals reversed that decision, ruling the exclusion was improper and reviving the federal litigation. State-court cases in Illinois, California, Texas, Florida, and Pennsylvania remain active throughout.
Who Qualifies for a Tylenol Autism Lawsuit
Eligibility focuses on mothers who used acetaminophen during pregnancy whose child was later diagnosed with autism spectrum disorder or ADHD. Claims may be brought against Kenvue, Johnson & Johnson, and retailers that sold generic acetaminophen, including CVS, Costco, Target, Walgreens, and Walmart.
Qualifying Criteria:
Scientific Evidence on Tylenol & Autism/ADHD
Multiple studies and reviews have reported associations between prenatal acetaminophen exposure and neurodevelopmental outcomes, including ASD and ADHD. Other experts urge caution, citing possible confounding and exposure misclassification. Courts weigh whether methods meet evidentiary standards, which differ between federal and state courts — a question now central to the reopened federal litigation.
Cell & Gene Research
Recent lab work notes changes in neurodevelopment pathways after APAP exposure, offering biological plausibility for the associations seen in observational studies.
Biomarker Studies
Umbilical-cord APAP biomarkers have been linked with higher odds of ASD and ADHD diagnoses in several published studies, including research out of Johns Hopkins.
Systematic Reviews
Researchers at Mount Sinai's Icahn School of Medicine analyzed dozens of studies and reported consistent evidence of associations between prenatal acetaminophen exposure and both ASD and ADHD — findings the 2nd Circuit's July 2026 ruling cited as part of why the excluded expert testimony deserved to be heard by a jury.
Tylenol Autism Litigation Timeline
| Period | Milestone |
|---|---|
| 2022–2023 | First Tylenol autism lawsuit filed (June 2022); JPML consolidates federal cases into MDL No. 3043 before Judge Denise Cote (October 2022); court excludes plaintiffs' experts on causation (December 2023). |
| 2024 | Judge Cote dismisses roughly 500 member cases and grants summary judgment, effectively ending the federal MDL pending appeal; state-court cases in Illinois and California continue. |
| 2025 | Trump administration issues a public warning tying Tylenol use in pregnancy to autism risk (September); plaintiffs urge the 2nd Circuit to weigh the federal government's stance; oral arguments held before the appeals court. |
| 🔴 July 13, 2026 | 2nd U.S. Circuit Court of Appeals reverses Judge Cote's exclusion of three plaintiff experts, reviving more than 500 federal lawsuits and returning them to the district court for further proceedings. |
See the full Tylenol Autism Lawsuit Updates section below for month-by-month detail.
Tylenol Autism Lawsuit Updates — 2026
Last updated July 2026. We update this section regularly with new case filings, appellate developments, trial dates, and regulatory actions.
-
July 13, 2026 🔴 BreakingAppeals Court Revives More Than 500 Tylenol Autism and ADHD Lawsuits: A unanimous three-judge panel of the 2nd U.S. Circuit Court of Appeals ruled that Judge Denise Cote improperly excluded testimony from three key plaintiff experts — Andrea Baccarelli (Harvard School of Public Health), Eric Hollander (Albert Einstein College of Medicine), and Brandon Pearson (Columbia University). The 64-page decision, authored by Circuit Judge Guido Calabresi, restores more than 500 lawsuits dismissed in December 2024 and returns them to Judge Cote for further proceedings. Kenvue says it will again seek to exclude the experts and maintains there is no proven link between acetaminophen and autism or ADHD. Kenvue shares dipped slightly on the news; the company's pending $40+ billion acquisition by Kimberly-Clark is expected to close later in 2026.
-
May 27, 2026Kenvue Updates Tylenol Label — No Autism Warning Added: Kenvue revised Tylenol's product label, but the update did not include any warning regarding autism or ADHD risk. The FDA has not provided an update on its earlier plans to consider adding an autism-related warning to the label.
-
March 10, 2026New Tylenol Lawsuits Filed in State Courts: Additional Tylenol autism and ADHD lawsuits were filed in state courts in Pennsylvania, Florida, and Illinois, as plaintiffs' firms continued building state-court litigation alongside the pending federal appeal.
-
February 26, 2026 RulingTexas Judge Refuses to Dismiss Attorney General's Tylenol Lawsuit: A lawsuit filed by Texas Attorney General Ken Paxton against Kenvue and Johnson & Johnson survived a motion to dismiss. Judge LeAnn Rafferty's order allows the case — alleging violation of the Texas Deceptive Trade Practices Act — to proceed.
-
December 1, 2025Appellate Court Considers the Lower Court's Dismissal of the MDL: The 2nd Circuit continued weighing whether Judge Cote properly excluded plaintiffs' expert testimony on causation — a decision that would ultimately determine whether the federal litigation could proceed.
-
September 29, 2025Plaintiffs Cite Trump Administration's Acetaminophen Warning: Plaintiffs asked the 2nd Circuit to consider new federal actions on acetaminophen and pregnancy, noting that the FDA and HHS relied on their expert, Dr. Andrea Baccarelli, when issuing pregnancy warnings and a nationwide "Dear Doctor" letter. The filing argued this supports allowing his testimony and that courts should not exclude evidence the executive branch had already endorsed.
-
September 26, 2025Hearing Rescheduled in Tylenol Appeal: The 2nd Circuit postponed oral arguments from October 6 to November 17 to allow the parties to review the government's new stance on acetaminophen. Federal officials were reportedly considering additional pregnancy-related warning language.
-
September 25, 2025Old Tylenol Tweet Resurfaces: HHS shared a 2017 post from Tylenol's social media account cautioning against use during pregnancy, drawing renewed attention as regulators reexamined acetaminophen safety guidance.
-
September 22, 2025Trump Links Tylenol to Autism: President Trump announced plans to warn against Tylenol use in pregnancy, suggesting a connection to autism. The effect on the pending 2nd Circuit appeal remained uncertain at the time.
-
September 10, 2025Appeal Hearing Scheduled: The 2nd Circuit set oral arguments for October 6 over whether Tylenol autism claims could proceed after the MDL judge dismissed them on scientific grounds.
-
September 8, 2025Autism Report Expected Soon: FDA leadership said the government's autism report should be released within a month, though acetaminophen might not be a central focus.
-
September 5, 2025Speculation on RFK Jr. Report: News outlets reported HHS might release findings linking Tylenol in pregnancy to autism, sparking a sharp drop in Kenvue's stock price.
-
August 26, 2025New Research Review: A Mount Sinai team analyzed dozens of studies and found consistent evidence of links between prenatal acetaminophen use and conditions like autism and ADHD, raising questions about past court rulings that had excluded such evidence.
-
February 22, 2025Biomarker Findings Published: A Nature Mental Health study found higher ADHD risk in children whose mothers had acetaminophen biomarkers during pregnancy, with stronger effects seen in girls.
-
January 3, 2025Earlier Oral Arguments: The 2nd Circuit heard arguments on whether expert testimony should have been excluded in the federal MDL.
-
September 4, 2024Future of Tylenol Litigation Uncertain: With federal Tylenol litigation effectively concluded by Judge Cote's summary judgment, the future of these lawsuits hung in the balance. Several pre-existing state court cases remained active: Bartle (Illinois) and Cooksey (Illinois) awaited rulings on motions to dismiss; Davey (California) had a trial date set for April 11, 2025; Fennewald (Illinois) and Bellmon (Illinois) had pending motions to dismiss.
-
August 22, 2024Federal Tylenol Litigation Concludes: Judge Cote's grant of summary judgment brought an end to the Tylenol litigation in federal court, absent a successful appeal — the ruling later reversed by the 2nd Circuit in July 2026.
-
July 15, 2024Tylenol MDL Judge Rejects New Evidence Linking Acetaminophen to ADHD: Judge Cote once again rejected a plaintiffs' expert witness, Dr. Roberta B. Ness, ruling her causation opinion unreliable and inadmissible due to methodological weaknesses. The ruling further weakened plaintiffs' position in federal court but did not affect state-court cases with different evidentiary standards.
-
May 28, 2024Tylenol MDL's Fate Hinges on Expert Opinion: The survival of the Tylenol MDL depended on Judge Cote's acceptance of Dr. Roberta Ness's opinion linking acetaminophen exposure during pregnancy to ADHD.
-
May 7, 2024New Expert Testimony: The MDL was never officially dismissed, and any path forward would rely on new expert testimony. The court gave Kenvue until July to object to the newly proposed medical expert testimony.
-
March 18, 2024New Tylenol ADHD Lawsuits Rely on New Evidence: Following a Daubert ruling excluding previous expert testimony, plaintiffs introduced a new expert, Dr. Roberta B. Ness, and research linking acetaminophen exposure during pregnancy to ADHD.
-
March 2024Judge Rules Against Tylenol-Autism Link: A Manhattan federal court judge denied expert witnesses from testifying about a link between Tylenol use during pregnancy and childhood autism, effectively preventing plaintiffs from using scientific studies in their cases at that stage.
-
February 21, 2024Judge Dismisses 500 Tylenol Cases: Judge Cote issued a final judgment dismissing approximately 500 member cases in the Tylenol MDL, citing plaintiffs' failure to provide a valid reason the cases should not be dismissed — the same 500+ cases later revived on appeal in 2026.
-
January 18, 2024Plaintiffs Face Dismissal: Plaintiffs in the Tylenol MDL were required to show valid reason by February 1 why their cases should not be dismissed, following Short Form Complaints issued on or before January 11, 2024. This affected 501 plaintiffs.
-
December 7, 2023MDL Dismissed on Causation Grounds: Judge Cote issued a 148-page ruling rejecting all five of plaintiffs' expert witnesses on the issue of causation. Kenvue announced it would seek to dismiss the federal MDL.
Find Out If Your Family Qualifies — Free Case Review
Attorneys are reviewing Tylenol autism and ADHD cases nationwide. You pay nothing unless compensation is recovered.
Start My Free Case ReviewHow the Tylenol Autism Lawsuit Process Works
Attorneys handle Tylenol autism cases on contingency — you pay nothing unless compensation is recovered.
- Free evaluation — Answer a few questions and share prenatal usage details with an attorney at no cost.
- Investigation — Your attorney gathers OB and pediatric records, pharmacy logs, and arranges expert review of your case.
- Filing — If eligible, a complaint may be filed in state court or joined to the reopened federal litigation, depending on the facts of your case.
- Discovery & negotiation — Both sides exchange evidence; your attorney pursues settlement where appropriate.
- Resolution — Settlement, mediation, or trial depending on facts and venue. You have the final say on any offer.
Start your free claim review — no upfront fees.
Why Trust InjuryClaims.com
We're a Florida Bar–registered Qualifying Provider connecting consumers to vetted law firms. Partner firms handle representation; results depend on the unique facts of each case.
Frequently Asked Questions
Is there a Tylenol autism settlement?
No global settlement exists yet. As of July 2026, a federal appeals court revived more than 500 previously dismissed lawsuits, sending them back to the district court for further proceedings. State-court cases also continue moving forward. A revival of the federal litigation could increase pressure toward eventual settlement talks, but no timeline has been announced.
Can I still file if the federal MDL was dismissed?
Yes. As of July 2026, a federal appeals court reversed the ruling that had excluded key plaintiff experts, reviving over 500 federal lawsuits and reopening the door for the litigation to proceed. New claims may also be filed in state courts, subject to each state's procedures and deadlines. Get a free review to assess your options.
What is the current status of the Tylenol autism lawsuit? (July 2026)
On July 13, 2026, the 2nd U.S. Circuit Court of Appeals reversed Judge Denise Cote's exclusion of three plaintiff experts, reviving more than 500 federal lawsuits that had been dismissed in December 2024. The case returns to Judge Cote for further proceedings, and Kenvue says it will again challenge the experts' admissibility. Separately, a Texas AG lawsuit against Kenvue and Johnson & Johnson survived a motion to dismiss in February 2026, and new state-court cases continue to be filed in states including Florida, Illinois, and Pennsylvania.
What documents help an eligibility review?
OB and pediatric records, pharmacy logs or receipts, notes on the timing and frequency of acetaminophen use, and the child's diagnostic records. You don't need every document in hand before reaching out — your attorney can help identify and obtain what's needed.
How long do I have to file?
Deadlines vary by state (statutes of limitation/repose), and some rules differ for minors. It's best to get a free evaluation promptly rather than assume you're out of time.
How are mass torts different from class actions?
Mass torts keep claims individual, with each family's damages assessed on its own facts. Class actions consolidate everyone into one case with a uniform outcome. Tylenol autism claims are proceeding as a mass tort (MDL), not a class action.
Sources
- Preclinical research on APAP and neurodevelopment
- American Journal of Epidemiology: prenatal APAP & neurodevelopmental outcomes
- Johns Hopkins: umbilical-cord APAP biomarkers & ASD/ADHD
- CNBC/Reuters: 2nd Circuit revives Tylenol autism/ADHD lawsuits (July 13, 2026)
- InjuryClaims News: Tylenol Autism MDL coverage
Get a Free Case Review
Answer a few questions to see if you qualify. Your information is confidential. No upfront fees.
